Current Environment: Production

Warning

Recall Alert

There is an antibacterial antibiotic recall. Read more

617-667-3112

Department of Anesthesia, Critical Care and Pain Medicine | Education

Undergraduate School

St. Mary's Hospital and The Royal Postgraduate Medical Schools

1991, London, England, United Kingdom

Medical School

St. Mary's Hospital/Imperial College

1994, London, England, United Kingdom

Internship

St. Mary's Hospital

1995, London, England, United Kingdom

Residency

Pediatrics

St. Mary’s, St. Thomas’, Northwick Park, Royal Brompton & Harefield Hospitals

1999, London, England, United Kingdom

Fellowship

Cardiac Electrophysiology

Royal Brompton & Harefield, St. Bartholomew’s and The Heart/University College Hospitals

2007, London, England, United Kingdom

Department of Anesthesia, Critical Care and Pain Medicine | Publications

  1. Perioperative Outcomes for Children With Cardiomyopathy Undergoing Noncardiac Procedures. Paediatr Anaesth. 2025 May 02. View Perioperative Outcomes for Children With Cardiomyopathy Undergoing Noncardiac Procedures. Abstract

  2. NAXCARE: a clinical outcome registry for Naxos disease and related cardiocutaneous syndromes. Hellenic J Cardiol. 2025 Apr 30. View NAXCARE: a clinical outcome registry for Naxos disease and related cardiocutaneous syndromes. Abstract

  3. Combining polygenic and clinical risk scores in atrial fibrillation risk prediction: Implications for population screening. Heart Rhythm. 2025 Apr 25. View Combining polygenic and clinical risk scores in atrial fibrillation risk prediction: Implications for population screening. Abstract

  4. Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Circulation. 2025 Mar 18; 151(11):e762. View Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Abstract

  5. Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2025 Feb; 18(1):e004641. View Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy. Abstract

  6. Clinical features and outcomes in carriers of pathogenic desmoplakin variants. Eur Heart J. 2025 Jan 21; 46(4):362-376. View Clinical features and outcomes in carriers of pathogenic desmoplakin variants. Abstract

  7. Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Circulation. 2025 Mar 18; 151(11):783-798. View Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Abstract

  8. A Natural History Study of Timothy Syndrome. Orphanet J Rare Dis. 2024 Nov 23; 19(1):433. View A Natural History Study of Timothy Syndrome. Abstract

  9. The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Heart Fail. 2025 Feb; 13(2):332-343. View The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy. Abstract

  10. Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy. J Am Heart Assoc. 2024 Nov 05; 13(21):e036208. View Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy. Abstract

  11. Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Circulation. 2024 Oct 22; 150(17):1377-1390. View Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry. Abstract

  12. A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Eur Heart J. 2024 Aug 21; 45(32):2968-2979. View A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Abstract

  13. Antisense Oligonucleotide Therapy for Calmodulinopathy. Circulation. 2024 Oct 08; 150(15):1199-1210. View Antisense Oligonucleotide Therapy for Calmodulinopathy. Abstract

  14. Management of ultrarare inherited arrhythmia syndromes. Heart Rhythm. 2025 Mar; 22(3):832-843. View Management of ultrarare inherited arrhythmia syndromes. Abstract

  15. Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study. Circulation. 2024 Aug 13; 150(7):516-530. View Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study. Abstract

  16. A Natural History Study of Timothy Syndrome. medRxiv. 2024 May 21. View A Natural History Study of Timothy Syndrome. Abstract

  17. Premature ventricular contractions in children and young adults: natural history and clinical implications. Europace. 2024 Mar 01; 26(3). View Premature ventricular contractions in children and young adults: natural history and clinical implications. Abstract

  18. Long-Term Arrhythmic Follow-Up and Risk Stratification of Patients With Desmoplakin-Associated Arrhythmogenic Right Ventricular Cardiomyopathy. JACC Adv. 2024 Mar; 3(3):100832. View Long-Term Arrhythmic Follow-Up and Risk Stratification of Patients With Desmoplakin-Associated Arrhythmogenic Right Ventricular Cardiomyopathy. Abstract

  19. Hypertrophic Cardiomyopathy and Ventricular Preexcitation in the Young: Cause and Accessory Pathway Characteristics. Circ Arrhythm Electrophysiol. 2023 11; 16(11):e012191. View Hypertrophic Cardiomyopathy and Ventricular Preexcitation in the Young: Cause and Accessory Pathway Characteristics. Abstract

  20. Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry. Circulation. 2023 08; 148(5):394-404. View Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry. Abstract

  21. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2023 Jul; 32(7):790-797. View Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia. Abstract

  22. Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor. Curr Opin Cardiol. 2023 07 01; 38(4):390-395. View Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor. Abstract

  23. Cascade testing for inherited cardiac conditions: Risk perception and screening after a negative genetic test result. J Genet Couns. 2022 12; 31(6):1273-1281. View Cascade testing for inherited cardiac conditions: Risk perception and screening after a negative genetic test result. Abstract

  24. Radiofrequency Catheter Ablation for Pediatric Atrioventricular Nodal Reentrant Tachycardia: Impact of Age on Procedural Methods and Durable Success. J Am Heart Assoc. 2022 06 21; 11(12):e022799. View Radiofrequency Catheter Ablation for Pediatric Atrioventricular Nodal Reentrant Tachycardia: Impact of Age on Procedural Methods and Durable Success. Abstract

  25. Familial Recurrence Patterns in Congenitally Corrected Transposition of the Great Arteries: An International Study. Circ Genom Precis Med. 2022 06; 15(3):e003464. View Familial Recurrence Patterns in Congenitally Corrected Transposition of the Great Arteries: An International Study. Abstract

  26. Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis. Circ Genom Precis Med. 2022 06; 15(3):e003507. View Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis. Abstract

  27. Sudden Cardiac Arrest in the Paediatric Population. CJC Pediatr Congenit Heart Dis. 2022 Apr; 1(2):45-59. View Sudden Cardiac Arrest in the Paediatric Population. Abstract

  28. Exercise Recommendations in Pediatric HCM: Variation and Influence of Provider Characteristics. Pediatr Cardiol. 2022 Jan; 43(1):132-141. View Exercise Recommendations in Pediatric HCM: Variation and Influence of Provider Characteristics. Abstract

  29. Accessory pathway ablation in Ebstein anomaly: A challenging substrate. Heart Rhythm. 2021 11; 18(11):1844-1851. View Accessory pathway ablation in Ebstein anomaly: A challenging substrate. Abstract

  30. 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. J Arrhythm. 2021 Jun; 37(3):481-534. View 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Abstract

  31. Lead age as a predictor for failure in pediatrics and congenital heart disease. Pacing Clin Electrophysiol. 2021 04; 44(4):586-594. View Lead age as a predictor for failure in pediatrics and congenital heart disease. Abstract

  32. Causal Genetic Variants in Stillbirth. N Engl J Med. 2020 12 31; 383(27):2687. View Causal Genetic Variants in Stillbirth. Abstract

  33. Cardiocutaneous Features of Autosomal Dominant Desmoplakin-Associated Arrhythmogenic Cardiomyopathy. Circ Genom Precis Med. 2020 12; 13(6):e003081. View Cardiocutaneous Features of Autosomal Dominant Desmoplakin-Associated Arrhythmogenic Cardiomyopathy. Abstract

  34. 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm. 2021 01; 18(1):e1-e50. View 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Abstract

  35. Risk Factors for Early Recurrence Following Ablation for Accessory Pathways: The Role of Consolidation Lesions. Circ Arrhythm Electrophysiol. 2020 11; 13(11):e008848. View Risk Factors for Early Recurrence Following Ablation for Accessory Pathways: The Role of Consolidation Lesions. Abstract

  36. Value of provocative electrophysiology testing in the management of pediatric patients after congenital heart surgery. Pacing Clin Electrophysiol. 2020 09; 43(9):901-907. View Value of provocative electrophysiology testing in the management of pediatric patients after congenital heart surgery. Abstract

  37. An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2020 09 08; 142(10):932-947. View An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Abstract

  38. Clinical and Genetic Findings in Children Presenting With Ventricular Fibrillation as the First Manifestation of Cardiovascular Disease. J Am Heart Assoc. 2020 05 18; 9(10):e016322. View Clinical and Genetic Findings in Children Presenting With Ventricular Fibrillation as the First Manifestation of Cardiovascular Disease. Abstract

  39. Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy. J Am Heart Assoc. 2020 02 04; 9(3):e015702. View Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy. Abstract

  40. Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. Heart Rhythm. 2020 06; 17(6):984-990. View Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. Abstract

  41. An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. Circulation. 2020 02 11; 141(6):429-439. View An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. Abstract

  42. Outcomes of catheter ablation of anteroseptal and midseptal accessory pathways in pediatric patients. Heart Rhythm. 2020 05; 17(5 Pt A):759-767. View Outcomes of catheter ablation of anteroseptal and midseptal accessory pathways in pediatric patients. Abstract

  43. Arrhythmia Mechanisms and Outcomes of Ablation in Pediatric Patients With Congenital Heart Disease. Circ Arrhythm Electrophysiol. 2019 11; 12(11):e007663. View Arrhythmia Mechanisms and Outcomes of Ablation in Pediatric Patients With Congenital Heart Disease. Abstract

  44. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm. 2019 11; 16(11):e373-e407. View 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Abstract

  45. Molecular mechanisms of arrhythmogenic cardiomyopathy. Nat Rev Cardiol. 2019 09; 16(9):519-537. View Molecular mechanisms of arrhythmogenic cardiomyopathy. Abstract

  46. Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents. J Am Coll Cardiol. 2019 07 23; 74(3):346-358. View Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents. Abstract

  47. Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue. Circulation. 2019 07 30; 140(5):390-404. View Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue. Abstract

  48. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca2+/Calmodulin-Dependent Kinase II. Circulation. 2019 07 30; 140(5):405-419. View Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca2+/Calmodulin-Dependent Kinase II. Abstract

  49. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 11; 16(11):e301-e372. View 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Abstract

  50. Overlooked Leadership Potential: The Preference for Leadership Potential in Job Candidates Who Are Men vs. Women. Front Psychol. 2019; 10:755. View Overlooked Leadership Potential: The Preference for Leadership Potential in Job Candidates Who Are Men vs. Women. Abstract

  51. Phenotypic Characterization of Individuals With Variants in Cardiovascular Genes in the Absence of a Primary Cardiovascular Indication for Testing. Circ Genom Precis Med. 2019 03; 12(3):e002463. View Phenotypic Characterization of Individuals With Variants in Cardiovascular Genes in the Absence of a Primary Cardiovascular Indication for Testing. Abstract

  52. International Triadin Knockout Syndrome Registry. Circ Genom Precis Med. 2019 02; 12(2):e002419. View International Triadin Knockout Syndrome Registry. Abstract

  53. The Real-World Utility of the LINQ Implantable Loop Recorder in Pediatric and Adult Congenital Heart Patients. JACC Clin Electrophysiol. 2019 02; 5(2):245-251. View The Real-World Utility of the LINQ Implantable Loop Recorder in Pediatric and Adult Congenital Heart Patients. Abstract

  54. Genetic Testing for Inherited Cardiac Arrhythmias: Current State-of-the-Art and Future Avenues. J Innov Card Rhythm Manag. 2018 Nov; 9(11):3406-3416. View Genetic Testing for Inherited Cardiac Arrhythmias: Current State-of-the-Art and Future Avenues. Abstract

  55. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Europace. 2018 11 01; 20(11):1719-1753. View Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. Abstract

  56. Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects. Heart Lung Circ. 2019 Jan; 28(1):22-30. View Channelopathies That Lead to Sudden Cardiac Death: Clinical and Genetic Aspects. Abstract

  57. SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. Eur Heart J. 2018 08 14; 39(31):2879-2887. View SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups. Abstract

  58. Utility of incomplete right bundle branch block as an isolated ECG finding in children undergoing initial cardiac evaluation. Congenit Heart Dis. 2018 May; 13(3):419-427. View Utility of incomplete right bundle branch block as an isolated ECG finding in children undergoing initial cardiac evaluation. Abstract

  59. Postmortem Genetic Testing for Cardiac Ion Channelopathies in Stillbirths. Circ Genom Precis Med. 2018 01; 11(1):e001817. View Postmortem Genetic Testing for Cardiac Ion Channelopathies in Stillbirths. Abstract

  60. Cardiac Conduction System in Congenitally Corrected Transposition of the Great Arteries and Its Clinical Relevance. J Am Heart Assoc. 2017 12 21; 6(12). View Cardiac Conduction System in Congenitally Corrected Transposition of the Great Arteries and Its Clinical Relevance. Abstract

  61. Dynamic QT Interval Changes from Supine to Standing in Healthy Children. Can J Cardiol. 2018 01; 34(1):66-72. View Dynamic QT Interval Changes from Supine to Standing in Healthy Children. Abstract

  62. Genotype-phenotype-guided medical and surgical intervention in long QT syndrome. HeartRhythm Case Rep. 2018 Jan; 4(1):14-17. View Genotype-phenotype-guided medical and surgical intervention in long QT syndrome. Abstract

  63. Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. JAMA Cardiol. 2017 10 01; 2(10):1153-1160. View Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. Abstract

  64. Cardiac Events During Competitive, Recreational, and Daily Activities in Children and Adolescents With Long QT Syndrome. J Am Heart Assoc. 2017 Sep 21; 6(9). View Cardiac Events During Competitive, Recreational, and Daily Activities in Children and Adolescents With Long QT Syndrome. Abstract

  65. Circadian Variation of Ventricular Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. JACC Clin Electrophysiol. 2017 11; 3(11):1308-1317. View Circadian Variation of Ventricular Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. Abstract

  66. Ebstein Anomaly. Card Electrophysiol Clin. 2017 06; 9(2):245-254. View Ebstein Anomaly. Abstract

  67. How to develop a clinic for sudden cardiac arrest survivors and families of non-survivors. Cardiol Young. 2017 Jan; 27(S1):S3-S9. View How to develop a clinic for sudden cardiac arrest survivors and families of non-survivors. Abstract

  68. Relation of Left Atrial Size to Atrial Fibrillation in Patients Aged =22 Years. Am J Cardiol. 2017 Jan 01; 119(1):52-56. View Relation of Left Atrial Size to Atrial Fibrillation in Patients Aged =22 Years. Abstract

  69. Whole-Exome Molecular Autopsy After Exertional Sudden Cardiac Death: Not a Panacea but a Step in the Right Direction. Circ Cardiovasc Genet. 2016 06; 9(3):210-2. View Whole-Exome Molecular Autopsy After Exertional Sudden Cardiac Death: Not a Panacea but a Step in the Right Direction. Abstract

  70. Radiofrequency ablation of atrial tachyarrhythmias in adults with tetralogy of Fallot - predictors of success and outcome. Cardiol Young. 2017 Mar; 27(2):284-293. View Radiofrequency ablation of atrial tachyarrhythmias in adults with tetralogy of Fallot - predictors of success and outcome. Abstract

  71. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: Developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and Congenital Cardiology (AEPC). Heart Rhythm. 2016 06; 13(6):e251-89. View PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: Developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and Congenital Cardiology (AEPC). Abstract

  72. Response to Letters Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation". Circulation. 2016 Jan 26; 133(4):e366-7. View Response to Letters Regarding Article, "Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation". Abstract

  73. Evolution of Electrocardiographic and Structural Features Over 3 Decades in Arrhythmogenic Cardiomyopathy. Circulation. 2015 Jun 23; 131(25):2233-5. View Evolution of Electrocardiographic and Structural Features Over 3 Decades in Arrhythmogenic Cardiomyopathy. Abstract

  74. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. Circulation. 2015 Jun 23; 131(25):2185-93. View Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. Abstract

  75. Mechanism and ablation of arrhythmia following total cavopulmonary connection. Circ Arrhythm Electrophysiol. 2015 Apr; 8(2):318-25. View Mechanism and ablation of arrhythmia following total cavopulmonary connection. Abstract

  76. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy. Circ Arrhythm Electrophysiol. 2014 Dec; 7(6):1057-63. View Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy. Abstract

  77. Implantable cardioverter-defibrillators in children. Arch Dis Child. 2015 Mar; 100(3):265-70. View Implantable cardioverter-defibrillators in children. Abstract

  78. Sudden arrhythmic death syndrome: diagnostic yield of comprehensive clinical evaluation of pediatric first-degree relatives. Pacing Clin Electrophysiol. 2014 Dec; 37(12):1681-5. View Sudden arrhythmic death syndrome: diagnostic yield of comprehensive clinical evaluation of pediatric first-degree relatives. Abstract

  79. Long QT syndrome. Circulation. 2014 Apr 08; 129(14):1524-9. View Long QT syndrome. Abstract

  80. Feasibility and outcomes of ajmaline provocation testing for Brugada syndrome in children in a specialist paediatric inherited cardiovascular diseases centre. Open Heart. 2014; 1(1):e000023. View Feasibility and outcomes of ajmaline provocation testing for Brugada syndrome in children in a specialist paediatric inherited cardiovascular diseases centre. Abstract

  81. Transbaffle mapping and ablation for atrial tachycardias after mustard, senning, or Fontan operations. J Am Heart Assoc. 2013 Sep 19; 2(5):e000325. View Transbaffle mapping and ablation for atrial tachycardias after mustard, senning, or Fontan operations. Abstract

  82. The role of cardiac resynchronization therapy for arterial switch operations complicated by complete heart block. Ann Thorac Surg. 2013 Sep; 96(3):904-9. View The role of cardiac resynchronization therapy for arterial switch operations complicated by complete heart block. Abstract

  83. The use of an integrated electroanatomic mapping system and intracardiac echocardiography to reduce radiation exposure in children and young adults undergoing ablation of supraventricular tachycardia. Europace. 2014 Feb; 16(2):277-83. View The use of an integrated electroanatomic mapping system and intracardiac echocardiography to reduce radiation exposure in children and young adults undergoing ablation of supraventricular tachycardia. Abstract

  84. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013 Sep; 15(9):1337-82. View Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Abstract

  85. The electrophysiological characteristics of accessory pathways in pediatric patients with intermittent preexcitation. Pacing Clin Electrophysiol. 2013 Sep; 36(9):1117-22. View The electrophysiological characteristics of accessory pathways in pediatric patients with intermittent preexcitation. Abstract

  86. Current genomics in cardiovascular medicine. Curr Genomics. 2012 Sep; 13(6):446-62. View Current genomics in cardiovascular medicine. Abstract

  87. Chest pain and ST elevation. BMJ. 2012 Jun 27; 344:e4323. View Chest pain and ST elevation. Abstract

  88. Variable QRS morphologies in Ebstein's anomaly: what is the mechanism? Heart Rhythm. 2013 Jun; 10(6):933-7. View Variable QRS morphologies in Ebstein's anomaly: what is the mechanism? Abstract

  89. The DSPII splice variant is crucial for desmosome-mediated adhesion in HaCaT keratinocytes. J Cell Sci. 2012 Jun 15; 125(Pt 12):2853-61. View The DSPII splice variant is crucial for desmosome-mediated adhesion in HaCaT keratinocytes. Abstract

  90. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011 Oct 20; 365(16):1502-8. View Inflammatory skin and bowel disease linked to ADAM17 deletion. Abstract

  91. Accuracy of algorithms to predict accessory pathway location in children with Wolff-Parkinson-White syndrome. Heart. 2012 Feb; 98(3):202-6. View Accuracy of algorithms to predict accessory pathway location in children with Wolff-Parkinson-White syndrome. Abstract

  92. Wherein lies children's intergroup bias? Egocentrism, social understanding, and social projection. Child Dev. 2011 Sep-Oct; 82(5):1579-93. View Wherein lies children's intergroup bias? Egocentrism, social understanding, and social projection. Abstract

  93. Does ventricular dyssynchrony on echocardiography predict response to cardiac resynchronisation therapy? A randomised controlled study. Heart. 2011 Sep; 97(17):1410-6. View Does ventricular dyssynchrony on echocardiography predict response to cardiac resynchronisation therapy? A randomised controlled study. Abstract

  94. Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? J Cardiovasc Electrophysiol. 2011 Mar; 22(3):265-70. View Catheter ablation for atrial fibrillation on uninterrupted warfarin: can it be done without echo guidance? Abstract

  95. [Long QT syndrome]. Praxis (Bern 1994). 2010 Jul 07; 99(14):854-8. View [Long QT syndrome]. Abstract

  96. Identification and characterization of DSPIa, a novel isoform of human desmoplakin. Cell Tissue Res. 2010 Jul; 341(1):121-9. View Identification and characterization of DSPIa, a novel isoform of human desmoplakin. Abstract

  97. Resolution of dyssynchronous left ventricular failure via cardiac resynchronization and subsequent radiofrequency ablation in an infant with pre-excitation. Pediatr Cardiol. 2010 Aug; 31(6):897-900. View Resolution of dyssynchronous left ventricular failure via cardiac resynchronization and subsequent radiofrequency ablation in an infant with pre-excitation. Abstract

  98. Long QT syndrome. BMJ. 2010 Jan 08; 340:b4815. View Long QT syndrome. Abstract

  99. Cryoablation versus radiofrequency ablation for treatment of atrioventricular nodal reentrant tachycardia: cryoablation with 6-mm-tip catheters is still less effective than radiofrequency ablation. Heart Rhythm. 2010 Mar; 7(3):340-3. View Cryoablation versus radiofrequency ablation for treatment of atrioventricular nodal reentrant tachycardia: cryoablation with 6-mm-tip catheters is still less effective than radiofrequency ablation. Abstract

  100. Validation of a classification system to grade fractionation in atrial fibrillation and correlation with automated detection systems. Europace. 2009 Dec; 11(12):1587-96. View Validation of a classification system to grade fractionation in atrial fibrillation and correlation with automated detection systems. Abstract

  101. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy. J Cardiovasc Electrophysiol. 2010 Feb; 21(2):150-4. View Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy. Abstract

  102. Electrophysiologic and anatomic characterization of sites resistant to electrical isolation during circumferential pulmonary vein ablation for atrial fibrillation: a prospective study. J Cardiovasc Electrophysiol. 2007 Dec; 18(12):1282-8. View Electrophysiologic and anatomic characterization of sites resistant to electrical isolation during circumferential pulmonary vein ablation for atrial fibrillation: a prospective study. Abstract

  103. Comparison of noncontact and electroanatomic mapping to identify scar and arrhythmia late after the Fontan procedure. Circulation. 2007 Apr 03; 115(13):1738-46. View Comparison of noncontact and electroanatomic mapping to identify scar and arrhythmia late after the Fontan procedure. Abstract

  104. Invasive electrophysiology in paediatric and congenital heart disease. Heart. 2007 Mar; 93(3):383-91. View Invasive electrophysiology in paediatric and congenital heart disease. Abstract

  105. The impact of CT image integration into an electroanatomic mapping system on clinical outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2006 Oct; 17(10):1093-101. View The impact of CT image integration into an electroanatomic mapping system on clinical outcomes of catheter ablation of atrial fibrillation. Abstract

  106. Successful ablation of atrioventricular nodal reentry tachycardia following the atriopulmonary Fontan procedure. Europace. 2006 Oct; 8(10):907-10. View Successful ablation of atrioventricular nodal reentry tachycardia following the atriopulmonary Fontan procedure. Abstract

  107. Validation of the noncontact mapping system in the left atrium during permanent atrial fibrillation and sinus rhythm. J Am Coll Cardiol. 2006 Aug 01; 48(3):485-91. View Validation of the noncontact mapping system in the left atrium during permanent atrial fibrillation and sinus rhythm. Abstract

  108. Radiofrequency ablation of arrhythmias guided by non-fluoroscopic catheter location: a prospective randomized trial. Eur Heart J. 2006 May; 27(10):1223-9. View Radiofrequency ablation of arrhythmias guided by non-fluoroscopic catheter location: a prospective randomized trial. Abstract

  109. Validation of three-dimensional cardiac image integration: use of integrated CT image into electroanatomic mapping system to perform catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2006 Apr; 17(4):341-8. View Validation of three-dimensional cardiac image integration: use of integrated CT image into electroanatomic mapping system to perform catheter ablation of atrial fibrillation. Abstract

  110. Transhepatic pulmonary artery stenting via a short intravascular sheath following neonatal repair of truncus arteriosus. Catheter Cardiovasc Interv. 2005 Oct; 66(2):277-80. View Transhepatic pulmonary artery stenting via a short intravascular sheath following neonatal repair of truncus arteriosus. Abstract

  111. Mechanism and mapping of atrial arrhythmia in the modified Fontan circulation. Heart Rhythm. 2005 Oct; 2(10):1138-44. View Mechanism and mapping of atrial arrhythmia in the modified Fontan circulation. Abstract

  112. Catheter ablation of permanent atrial fibrillation: medium term results. Heart. 2006 Feb; 92(2):233-8. View Catheter ablation of permanent atrial fibrillation: medium term results. Abstract

  113. Prolapse of the antero-superior leaflet of the tricuspid valve secondary to congenital anomalies of the valvar and sub-valvar apparatus: a rare cause of severe tricuspid regurgitation. Cardiol Young. 2005 Aug; 15(4):417-21. View Prolapse of the antero-superior leaflet of the tricuspid valve secondary to congenital anomalies of the valvar and sub-valvar apparatus: a rare cause of severe tricuspid regurgitation. Abstract

  114. Images in cardiovascular medicine. Membranous pulmonary atresia treated by radiofrequency-assisted balloon pulmonary valvotomy. Circulation. 2003 Apr 22; 107(15):e98-9. View Images in cardiovascular medicine. Membranous pulmonary atresia treated by radiofrequency-assisted balloon pulmonary valvotomy. Abstract

  115. Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group. Clin Infect Dis. 1993 Jun; 16(6):816-22; discussion 823-4. View Guidelines for the design and conduct of AIDS clinical trials. AIDS Clinical Trials Group. Abstract

  116. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis. 1989 Jun; 159(6):1029-36. View Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. Abstract

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

I am unable to answer specific questions regarding your child's case, including appointments and conditions/diagnosis. Please contact your physician's office.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services